Literature DB >> 20421546

Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results.

Felix Y Feng1, Hyungjin M Kim, Teresa H Lyden, Marc J Haxer, Francis P Worden, Mary Feng, Jeffrey S Moyer, Mark E Prince, Thomas E Carey, Gregory T Wolf, Carol R Bradford, Douglas B Chepeha, Avraham Eisbruch.   

Abstract

PURPOSE: To assess clinical and functional results of chemoradiotherapy for oropharyngeal cancer (OPC), utilizing intensity-modulated radiotherapy (IMRT) to spare the important swallowing structures to reduce post-therapy dysphagia. PATIENTS AND METHODS: This was a prospective study of weekly chemotherapy (carboplatin dosed at one times the area under the curve [AUC, AUC 1] and paclitaxel 30 mg/m(2)) concurrent with IMRT aiming to spare noninvolved parts of the swallowing structures: pharyngeal constrictors, glottic and supraglottic larynx, and esophagus as well as the oral cavity and major salivary glands. Swallowing was assessed by patient-reported Swallowing and Eating Domain scores, observer-rated scores, and videofluoroscopy (VF) before therapy and periodically after therapy through 2 years.
RESULTS: Overall, 73 patients with stages III to IV OPC participated. At a median follow-up of 36 months, 3-year disease-free and locoregional recurrence-free survivals were 88% and 96%, respectively. All measures of dysphagia worsened soon after therapy; observer-rated and patient-reported scores recovered over time, but VF scores did not. At 1 year after therapy, observer-rated dysphagia was absent or minimal (scores 0 to 1) in all patients except four: one who was feeding-tube dependent and three who required soft diet. From pretherapy to 12 months post-therapy, the Swallowing and Eating Domain scores worsened on average (+/- standard deviation) by 10 +/- 21 and 13 +/- 19, respectively (on scales of 0 to 100), and VF scores (on scale of 1 to 7) worsened from 2.9 +/- 1.5 (mild dysphagia) to 4.1 +/- 0.9 (mild/moderate dysphagia).
CONCLUSION: Chemoradiotherapy with IMRT aiming to reduce dysphagia can be performed safely for OPC and has high locoregional tumor control rates. On average, long-term patient-reported, observer-rated, and objective measures of swallowing were only slightly worse than pretherapy measures, representing potential improvement compared with previous studies.

Entities:  

Mesh:

Year:  2010        PMID: 20421546      PMCID: PMC2881852          DOI: 10.1200/JCO.2009.24.6199

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  45 in total

Review 1.  Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.

Authors:  Geoffrey R Norman; Jeff A Sloan; Kathleen W Wyrwich
Journal:  Med Care       Date:  2003-05       Impact factor: 2.983

2.  Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer.

Authors:  Gordon O Schoenfeld; Robert J Amdur; Christopher G Morris; Jonathan G Li; Russell W Hinerman; William M Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-31       Impact factor: 7.038

3.  Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer.

Authors:  Avraham Eisbruch; Teresa Lyden; Carol R Bradford; Laura A Dawson; Marc J Haxer; Amy E Miller; Theodoros N Teknos; Douglas B Chepeha; Norman D Hogikyan; Jeffrey E Terrell; Gregory T Wolf
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-05-01       Impact factor: 7.038

4.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

5.  Xerostomia: 12-month changes in saliva production and its relationship to perception and performance of swallow function, oral intake, and diet after chemoradiation.

Authors:  Jeri A Logemann; Barbara Roa Pauloski; Alfred W Rademaker; Cathy L Lazarus; Bharat Mittal; Joy Gaziano; Linda Stachowiak; Ellen MacCracken; Lisa A Newman
Journal:  Head Neck       Date:  2003-06       Impact factor: 3.147

6.  Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck.

Authors:  Tamar Kotz; Rosemary Costello; Yi Li; Marshall Roy Posner
Journal:  Head Neck       Date:  2004-04       Impact factor: 3.147

7.  Interrater reliability of videofluoroscopic swallow evaluation.

Authors:  Sandro J Stoeckli; Thierry A G M Huisman; Burkhardt Seifert; Bonnie J W Martin-Harris
Journal:  Dysphagia       Date:  2003       Impact factor: 3.438

8.  Assessment of quality of life in head and neck cancer patients.

Authors:  S J Hassan; E A Weymuller
Journal:  Head Neck       Date:  1993 Nov-Dec       Impact factor: 3.147

9.  Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing.

Authors:  Avraham Eisbruch; Lon H Marsh; Laura A Dawson; Carol R Bradford; Theodoros N Teknos; Douglas B Chepeha; Francis P Worden; Susan Urba; Alexander Lin; Matthew J Schipper; Gregory T Wolf
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-05-01       Impact factor: 7.038

10.  Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume.

Authors:  K S Clifford Chao; Gokhan Ozyigit; Angel I Blanco; Wade L Thorstad; Joseph O Deasy; Bruce H Haughey; Gershon J Spector; Donald G Sessions
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-05-01       Impact factor: 7.038

View more
  103 in total

1.  (18)F-FDG PET/CT to assess response and guide risk-stratified follow-up after chemoradiotherapy for oropharyngeal squamous cell carcinoma.

Authors:  Thomas Bird; Sally Barrington; Selvam Thavaraj; Jean-Pierre Jeannon; Andrew Lyons; Richard Oakley; Ricard Simo; Mary Lei; Teresa Guerrero Urbano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-28       Impact factor: 9.236

2.  Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin.

Authors:  Paul L Swiecicki; Pin Li; Emily Bellile; Chaz Stucken; Kelly Malloy; Andrew Shuman; Matthew E Spector; Steven Chinn; Keith Casper; Scott McLean; Jeffery Moyer; Douglas Chepeha; Gregory T Wolf; Mark Prince; Carol Bradford; Mukesh Nyati; Avraham Eisbruch; Francis P Worden; Shruti Jolly; Michelle Mierzwa
Journal:  Head Neck       Date:  2020-01-27       Impact factor: 3.147

3.  High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods.

Authors:  Heather M Walline; Chris Komarck; Jonathan B McHugh; Serena A Byrd; Matthew E Spector; Samantha J Hauff; Martin P Graham; Emily Bellile; Jeffrey S Moyer; Mark E Prince; Gregory T Wolf; Douglas B Chepeha; Francis P Worden; Matthew H Stenmark; Avraham Eisbruch; Carol R Bradford; Thomas E Carey
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2013-12       Impact factor: 6.223

Review 4.  Head and neck cancer in 2010: Maximizing survival and minimizing toxicity.

Authors:  Bruce E Brockstein; Everett E Vokes
Journal:  Nat Rev Clin Oncol       Date:  2011-02       Impact factor: 66.675

Review 5.  Organ-sparing radiation therapy for head and neck cancer.

Authors:  XiaoShen Wang; ChaoSu Hu; Avraham Eisbruch
Journal:  Nat Rev Clin Oncol       Date:  2011-07-26       Impact factor: 66.675

6.  Optimising Radiation Therapy Dose to the Swallowing Organs at Risk: An In Silico Study of feasibility for Patients with Oropharyngeal Tumours.

Authors:  Molly K Barnhart; Bena Cartmill; Elizabeth C Ward; Elizabeth Brown; Jonathon Sim; George Saade; Sandra Rayner; Rachelle A Robinson; Virginia A Simms; Robert I Smee
Journal:  Dysphagia       Date:  2019-02-11       Impact factor: 3.438

7.  Matted nodes: High distant-metastasis risk and a potential indication for intensification of systemic therapy in human papillomavirus-related oropharyngeal cancer.

Authors:  Jeffrey M Vainshtein; Matthew E Spector; Mohannad Ibrahim; Carol R Bradford; Gregory T Wolf; Matthew H Stenmark; Francis P Worden; Jonathan B McHugh; Mark E Prince; Thomas Carey; Douglas B Chepeha; Avraham Eisbruch
Journal:  Head Neck       Date:  2015-07-15       Impact factor: 3.147

Review 8.  Treatment de-intensification strategies for head and neck cancer.

Authors:  Jacqueline R Kelly; Zain A Husain; Barbara Burtness
Journal:  Eur J Cancer       Date:  2016-10-15       Impact factor: 9.162

9.  Transoral laser microsurgery followed by radiation therapy for oropharyngeal tumors: the Mayo Clinic Arizona experience.

Authors:  Samir H Patel; Michael L Hinni; Richard E Hayden; William W Wong; Amylou C Dueck; Matthew A Zarka; Kelly K Curtis; Michele Y Halyard
Journal:  Head Neck       Date:  2013-03-26       Impact factor: 3.147

10.  Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).

Authors:  C M L van Herpen; M E Mauer; R Mesia; M Degardin; S Jelic; C Coens; J Betka; J Bernier; E Remenar; J S Stewart; J H Preiss; D van den Weyngaert; A Bottomley; J B Vermorken
Journal:  Br J Cancer       Date:  2010-09-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.